Primary Familial Brain Calcification (Fahr'S Disease) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Primary familial brain calcification (PFBC), historically called Fahr disease, is a neurodegenerative syndrome characterized by bilateral intracranial calcifications and a heterogeneous movement, cognitive, and psychiatric phenotype. This page summarizes epidemiology, molecular mechanisms, diagnosis, and management. [@earlyonset]
Primary Familial Brain Calcification (Fahr'S Disease) is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches.
Primary familial brain calcification (PFBC), historically called Fahr disease, is a neurodegenerative syndrome characterized by bilateral intracranial calcifications and a heterogeneous movement, cognitive, and psychiatric phenotype. This page summarizes epidemiology, molecular mechanisms, diagnosis, and management. [@earlyonset]
<table class="infobox infobox-disease"> [@oral]
<tr> [@case]
<th class="infobox-header" colspan="2">Primary Familial Brain Calcification (Fahr's Disease)</th> [@pathophysiology]
</tr> [^6]
<tr> [^7]
<td class="infobox-image" colspan="2"> [^8]
<em>CT scan showing bilateral basal ganglia calcification</em> [^9]
</td> [^10]
</tr>
<tr>
<td class="label">Also Known As</td>
<td>Fahr's Disease, Fahr Syndrome, Bilateral Striopallidodentate Calcinosis, Idiopathic Basal Ganglia Calcification (IBGC)</td>
</tr>
<tr>
<td class="label">ICD-10</td>
<td>G23.8</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td><a href="https://www.omim.org/entry/213600" target="_blank">213600</a> (IBGC1); <a href="https://www.omim.org/entry/615483" target="_blank">615483</a> (IBGC3); <a href="https://www.omim.org/entry/615007" target="_blank">615007</a> (IBGC4)</td>
</tr>
<tr>
<td class="label">Inheritance</td>
<td>Autosomal dominant (SLC20A2, PDGFB, PDGFRB, XPR1); Autosomal recessive (MYORG, JAM2, NAA60)</td>
</tr>
<tr>
<td class="label">Key Genes</td>
<td><em>SLC20A2</em>, <em>PDGFB</em>, <em>PDGFRB</em>, <em>XPR1</em>, <em>MYORG</em>, <em>JAM2</em>, <em>NAA60</em></td>
</tr>
<tr>
<td class="label">Onset</td>
<td>Typically 40–60 years; variable</td>
</tr>
<tr>
<td class="label">Key Features</td>
<td>Bilateral brain calcification, parkinsonism, cognitive decline, psychiatric symptoms</td>
</tr>
<tr>
<td class="label">Prevalence</td>
<td>Rare; basal ganglia calcifications found in 0.24–2% of CT scans</td>
</tr>
</table>
Primary familial brain calcification (PFBC), historically known as Fahr's disease, is a rare neurodegenerative disorder characterized by bilateral, symmetric calcification of the [basal ganglia](/brain-regions/basal-ganglia) and other cerebral and cerebellar structures, particularly the [globus pallidus](/brain-regions/globus-pallidus), dentate nuclei, [thalamus](/brain-regions/thalamus), and subcortical white matter.[@importance] The condition was first described by Karl Theodor Fahr in 1930, though the genetic basis was not elucidated until the identification of SLC20A2 mutations in 2012.[@earlyonset]
PFBC is genetically heterogeneous, with seven causative genes identified to date.
Heterozygous pathogenic variants in SLC20A2, PDGFB, PDGFRB, or XPR1 cause autosomal dominant PFBC, while biallelic variants in MYORG, JAM2, or NAA60 cause autosomal recessive forms.[@oral] Clinical manifestations range from asymptomatic individuals with incidental radiographic findings to progressive movement disorders, cognitive decline, and psychiatric disturbances.
Up to one-third of genetically confirmed carriers remain asymptomatic even with extensive brain calcification.[@case]
The true prevalence of PFBC remains uncertain due to diagnostic challenges and the frequency of asymptomatic cases.
Population-based CT studies report incidental basal ganglia calcifications in 0.24–2% of consecutive scans, though most of these represent secondary causes rather than PFBC.[@pathophysiology] The condition affects males and females equally and has been reported across all ethnic groups, with SLC20A2 mutations accounting for approximately 40% of genetically confirmed families, making it the most common genetic cause.
PDGFB mutations are the second most frequent, and together the first three identified genes explain roughly 49% of PFBC families.[@oral]
The median age at symptom onset is approximately 43 years, though this varies by genotype. Carriers of PDGFB mutations tend to present significantly earlier than those with mutations in other genes.
Penetrance is incomplete and age-related, meaning that not all carriers of pathogenic variants develop clinical symptoms.[@case]
Two of the PFBC genes — SLC20A2 and XPR1 — encode phosphate transporters involved in maintaining cerebrospinal fluid (CSF) phosphate homeostasis:
The remaining genes converge on the integrity of the [neurovascular unit](/mechanisms/neurovascular-unit):
The convergent pathogenesis involves disruption of the neurovascular unit, where abnormal calcium-phosphorus metabolism, functional and microanatomical alterations of [pericytes](/cell-types/pericytes), and mitochondrial alterations cause BBB dysfunction and generation of an osteogenic environment. Surrounding [reactive astrogliosis](/mechanisms/reactive-astrogliosis) and progressive [neuroinflammation](/mechanisms/neuroinflammation) contribute to neurodegeneration.
Calcifications consist primarily of hydroxyapatite deposits along capillary walls, extending into the perivascular space and eventually into the neuropil.[^7]
Parkinsonism is the most common motor phenotype, presenting with bradykinesia, rigidity, tremor, and gait instability. Approximately 20% of symptomatic patients exhibit hyperkinetic movements, including chorea, [dystonia](/diseases/dystonia), and myoclonus. Cerebellar ataxia occurs in a subset of patients with prominent dentate nucleus calcification.
Pyramidal tract signs including hyperreflexia and spasticity may also be present.[@case]
Cognitive decline ranges from mild executive dysfunction to frank dementia, with predominantly subcortical features including impaired processing speed, attention deficits, and visuospatial dysfunction. Psychiatric manifestations are prominent and include mood disorders, psychosis with paranoid delusions and auditory hallucinations, personality changes, and anxiety.
These neuropsychiatric symptoms may precede motor findings by years and are frequently the presenting complaint.[^8]
Seizures occur in approximately 15–20% of symptomatic patients and may be focal or generalized. Headache, vertigo, and stroke-like episodes have also been reported. Recent studies suggest an association between PFBC and cerebrovascular events secondary to vascular calcification, including stroke and transient ischemic attacks.[@pathophysiology]
CT scan is the preferred modality for detecting brain calcification, as calcified deposits appear as hyperdense lesions in the basal ganglia and other regions. Calcification typically affects the lateral portion of the [globus pallidus](/brain-regions/globus-pallidus) first, then extends to the caudate nucleus, putamen, dentate nuclei, thalamus, and subcortical white matter.
MRI may show hypointensity on T1-weighted and susceptibility-weighted imaging (SWI), with variable signal on T2-weighted sequences depending on the calcium content and associated tissue changes.[^9]
The diagnosis of PFBC requires: (1) bilateral basal ganglia calcification demonstrated on neuroimaging; (2) progressive neurological or psychiatric symptoms; (3) exclusion of secondary causes (hypoparathyroidism, pseudohypoparathyroidism, metabolic disorders, infections, toxic exposures); (4) family history consistent with genetic transmission or identification of a pathogenic variant in a known PFBC gene.
Genetic testing confirms the diagnosis and is recommended for all patients meeting clinical and radiological criteria.[@importance]
Secondary causes of basal ganglia calcification must be excluded, including:
There is currently no disease-modifying treatment for PFBC. Management is symptomatic and supportive:
Potential therapeutic targets under investigation include:
Recent bibliometric and meta-analytic studies have expanded understanding of PFBC genotype-phenotype correlations. The identification of NAA60 as a seventh PFBC gene in 2024 highlights ongoing gene discovery efforts.
Transcriptomic studies of patient-derived cells are revealing downstream molecular pathways affected by each genetic cause, potentially identifying shared therapeutic targets across PFBC subtypes.[^10]
Research into the relationship between PFBC and other neurodegenerative diseases, particularly [Parkinson's disease](/diseases/parkinsons-disease) and [Vascular Dementia](/diseases/vascular-dementia), may clarify shared pathogenic mechanisms involving the neurovascular unit and BBB integrity.
Skin biopsy studies have identified increased extracranial calcification in PFBC patients, potentially offering a less invasive diagnostic biomarker.[^7]
The study of Primary Familial Brain Calcification (Fahr'S Disease) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.